Skip to main content
    4

    4D Molecular Therapeutics Inc (FDMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.29
    -0.94 (-7.69%)

    Market Cap: $689.52M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    4D Molecular Therapeutics Inc (FDMT) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    4D Molecular Therapeutics (FDMT) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, 4D Molecular Therapeutics reported EPS of -$1.08, below the -$1.04 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    36%(9/25)
    Avg Surprise
    -25.16%

    Upcoming Estimates

    Reports Mar 16, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.10
    Range-$1.19 - -$1.00
    13 analysts
    Revenue Consensus
    $3.67M
    RangeN/A
    11 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.13
    Range-$1.19 - -$1.06
    2 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.06-6.1%
    60d ago-$1.06-6.1%
    30d ago-$1.10-2.7%
    7d ago-$1.10-2.7%
    Current-$1.13
    Revenue Consensus
    $2.50M
    RangeN/A
    2 analysts

    Next Report

    FDMT has an expected report date of Mar 16, 2027.

    Earnings History

    Of the 25 quarters below that had an estimate, FDMT beat 9, missed 13 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $4.14M, up 4500.0% from $90000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.08-$1.04-$1.10 - -$0.99-3.85%MissN/A111 up, 1 downNov 12, 2026$4.14M
    Jun 30, 2026-$1.04-$1.04-$1.10 - -$0.890.00%In lineN/A90 up, 1 downAug 13, 2026$3.78M
    Mar 31, 2026-$1.01-$1.00-$1.32 - -$0.84-1.00%MissN/A90 up, 2 downMay 7, 2026$3.05M
    Dec 31, 2025$0.43-$0.53-$1.05 - $0.42+180.83%BeatN/A108 up, 1 downMar 18, 2026$85.21M
    Sep 30, 2025-$1.01-$0.98-$1.08 - -$0.80-3.06%MissN/A102 up, 8 downNov 10, 2025$90000
    Jun 30, 2025-$0.98-$0.69-$1.04 - $0.95-42.03%MissN/A100 up, 1 downAug 11, 2025$15000
    Mar 31, 2025-$0.86-$0.86-$1.05 - -$0.690.00%In lineN/A90 up, 1 downMay 8, 2025N/A
    Dec 31, 2024-$0.90-$0.84-$1.16 - -$0.57-7.41%MissN/A102 up, 2 downFeb 28, 2025$1000
    Sep 30, 2024-$0.79-$0.70-$0.80 - -$0.63-12.86%MissN/A80 up, 0 downNov 13, 2024N/A
    Jun 30, 2024-$0.63-$0.71-$0.81 - -$0.61+11.27%BeatN/A90 up, 0 downAug 8, 2024N/A
    Mar 31, 2024-$0.66-$0.76-$0.84 - -$0.68+13.16%BeatN/A60 up, 0 downMay 9, 2024N/A
    Dec 31, 2023-$0.75-$0.74-$0.87 - -$0.39-1.35%MissN/A82 up, 0 downFeb 29, 2024$519000
    Sep 30, 2023-$0.24-$0.60-$0.87 - -$0.27+60.00%BeatN/A60 up, 0 downNov 9, 2023$20.20M
    Jun 30, 2023-$0.77-$0.77-$0.89 - -$0.720.00%In lineN/A50 up, 0 downAug 9, 2023N/A
    Mar 31, 2023-$0.88-$0.90-$1.00 - -$0.78+2.22%BeatN/A50 up, 0 downMay 10, 2023N/A
    Dec 31, 2022-$0.84-$0.79-$0.95 - -$0.48-6.33%MissN/A50 up, 0 downMar 15, 2023$1.25M
    Sep 30, 2022-$0.79-$0.91-$1.11 - -$0.79+13.19%BeatN/A40 up, 0 downNov 8, 2022$500000
    Jun 30, 2022-$0.87-$0.85-$1.07 - -$0.69-2.35%MissN/A40 up, 0 downAug 11, 2022$162000
    Mar 31, 2022-$0.82-$0.77-$0.98 - -$0.68-6.49%MissN/A30 up, 0 downMay 12, 2022$1.22M
    Dec 31, 2021-$0.85-$0.86-$0.94 - -$0.79+1.16%BeatN/A30 up, 0 downMar 28, 2022$92000
    Sep 30, 2021-$0.82-$0.80-$0.83 - -$0.78-2.50%MissN/A2N/ANov 10, 2021$1.37M
    Jun 30, 2021-$0.28-$0.68-$0.71 - -$0.65+58.82%BeatN/A2N/AAug 12, 2021$14.58M
    Mar 31, 2021-$0.61-$1.10-$1.10 - -$1.10+44.55%BeatN/A1N/AMay 13, 2021$2.00M
    Dec 31, 2020-$2.36-$0.66-$0.66 - -$0.66-257.58%MissN/A1N/AMar 25, 2021N/A
    Sep 30, 2020-$3.07-$0.40N/A-667.50%MissN/AN/AN/ADec 16, 2020$7.42M
    Sep 30, 2019-$3.12N/AN/AN/AN/AN/AN/AN/ADec 31, 2019$540000
    Jun 30, 2019-$1.82N/AN/AN/AN/AN/AN/AN/ASep 30, 2019$2.21M
    Mar 31, 2019-$1.61N/AN/AN/AN/AN/AN/AN/AJun 29, 2019$2.21M
    Dec 31, 2018-$1.61N/AN/AN/AN/AN/AN/AN/AMar 30, 2019$4.53M
    Sep 30, 2018-$0.43N/AN/AN/AN/AN/AN/AN/ADec 31, 2018$4.53M
    Jun 30, 2018-$0.43N/AN/AN/AN/AN/AN/AN/ASep 30, 2018$2.53M
    Mar 31, 2018-$0.52N/AN/AN/AN/AN/AN/AN/AJun 29, 2018$2.53M
    Dec 31, 2017-$0.52N/AN/AN/AN/AN/AN/AN/AMar 30, 2018N/A
    Last 33 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.42, after -$2.98 the year before. It was -$0.52 for the year ended Dec 31, 2017, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.42N/A
    Dec 31, 2024-$2.98N/A
    Dec 31, 2023-$2.64N/A
    Dec 31, 2022-$3.32N/A
    Dec 31, 2021-$2.56N/A
    Dec 31, 2020-$11.98N/A
    Dec 31, 2018-$2.98N/A
    Dec 31, 2017-$0.52N/A

    Frequently Asked Questions About FDMT

    When is 4D Molecular Therapeutics's next earnings date?

    4D Molecular Therapeutics's next earnings report is expected for Mar 16, 2027.

    Did FDMT beat earnings estimates last quarter?

    No. 4D Molecular Therapeutics reported EPS of -$1.08 for the quarter ended Sep 30, 2026, below the -$1.04 estimate by 3.85%.

    What EPS do analysts expect from FDMT next quarter?

    The consensus EPS estimate for 4D Molecular Therapeutics for the quarter ending Dec 31, 2026 is -$1.10 from 13 analysts, with estimates from -$1.19 to -$1.00.

    How often does FDMT beat earnings estimates?

    4D Molecular Therapeutics beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of +15.43%.